Know Cancer

forgot password

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

Open (Enrolling)
Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer

Thank you

Trial Information

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

Inclusion Criteria:

- Patients with lymphoma or lymphoproliferative disease accepted for referral to the
Cancer Family Clinic of the Department of Human Genetics for genetic counseling, or
to the MSKCC outpatient clinics of the Lymphoma or Leukemia Services in the
Department of Medicine in consultation for treatment who are found on routine history
or through a Family History Questionnaire (FHQ) (Appendix A) to have relatives or
members of successive generations of the family affected with Hodgkin's disease,
non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma or other
lymphoproliferative disease. Patients with lymphoma, associated with colon and renal
cancer will be eligible for DNA storage through this protocol. Family members or
probands with Hodgkin's disease who are women who received therapeutic irradiation
for Hodgkin's disease" or who developed secondary cancers after Hodgkin's disease are
also eligible for participation.

- The criteria for eligibility are broad because the ascertainment by the computerized
FHQ does not allow for resolution of different types of lymphoma or different types
of leukemia. Patient recall of this information is also imprecise. More accurate
family history information will be obtained upon contact of family members and
diagnoses will be verified by obtaining pathologic documentation. The spectrum of
familial lymphoproliferative syndromes (LPS) may include all types of lymphoma as
well as chronic lymphocytic leukemia. This is an additional reason to have a broad
eligibility. Subset analysis will be performed on specific types of lymphoid
neoplasms. DNA of patients with a family history of lymphoma who have consented to
protocol 93-102 ("Ascertainment of Peripheral Blood or Saliva Samples for Genetic
Epidemiology Studies of Familial Cancers") will also be eligible for inclusion in
this study.

- Family members of probands including patients, sisters, brothers, halfbrothers and
sisters, sons, daughters, grandparents, as well as aunts and uncles are also
eligible. An effort will be made to ascertain all living affected and unaffected
living relatives in the affected lineage. An emphasis will be on affected sibling
pairs and both parents, if alive.

- As this study involves research that presents no greater than minimal risk to
children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible
for participation. The assent of any minor should be obtained before the patient is
enrolled into this study, as well as the consent of the legal guardian.

Exclusion Criteria:

- N/A

Type of Study:


Study Design:

Observational Model: Family-Based, Time Perspective: Prospective

Outcome Measure:

To establish a collection of DNA and frozen lymphocytes for the purpose of facilitating genetic laboratory investigations of familial lymphoid neoplasms.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Kenneth Offit, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

July 2000

Completion Date:

December 2013

Related Keywords:

  • Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Colon Cancer
  • Renal Cancer
  • Genetic Studies
  • 00-069
  • Colonic Neoplasms
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Leukemia
  • Lymphoma
  • Lymphoproliferative Disorders
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Memorial Sloan-Kettering Cancer Center New York, New York  10021